IPSC (Century Therapeutics) Beta: 2.4506 (As of Jul. 08, 2026)


IPSC Century Therapeutics Inc IPSC
46 GF Score
Price $2.32
GF Value $38.91
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Century Therapeutics Beta?

Century Therapeutics IPSC -3.75% 46 Beta is 2.4506 as of Jul. 08, 2026. GuruFocus rates IPSC with a GF Score™ of 46/100 and a GF Value™ of $38.91 (Possible Value Trap). The stock has 3 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-07-08), Century Therapeutics's Beta is 2.4506.


Century Therapeutics  (NAS:IPSC) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Century Therapeutics Beta Related Terms


Century Therapeutics Beta Historical Data

* Premium members only.

The historical data trend for Century Therapeutics's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Century Therapeutics Beta Chart

Century Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial 0.00 0.00 0.00 2.07 3.04

Century Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.27 2.73 3.41 3.04 2.74

IPSC vs PBYI, BNTC, ENTA: Beta Comparison

For the Biotechnology subindustry, Century Therapeutics's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Century Therapeutics Beta vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Century Therapeutics's Beta distribution charts can be found below:

* The bar in red indicates where Century Therapeutics's Beta falls into.


IPSC
46GF Score
Century Therapeutics Inc IPSC
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Century Therapeutics Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 2.4506 mean?
Century Therapeutics (IPSC) has a Beta of 2.4506 as of Jul. 08, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Century Therapeutics and its competitors.
Is Century Therapeutics' Beta too high?
Century Therapeutics' current Beta is 2.4506. Overall, Century Therapeutics has a GF Score™ of 46/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Century Therapeutics' Beta compare to PBYI and BNTC?
Century Therapeutics' Beta of 2.4506 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Biotechnology company?
A good Beta depends on the Biotechnology industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Century Therapeutics and its competitors. Century Therapeutics's current Beta is 2.4506. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Century Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Century Therapeutics (IPSC) is currently considered Possible Value Trap. The stock's GF Value™ is $38.91, compared to a current price of $2.32 — trading 94.1% below its estimated fair value. The current Beta is 2.4506. Century Therapeutics' overall GF Score™ is 46/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Century Therapeutics (IPSC), the current Beta is 2.4506 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Century Therapeutics (IPSC) Overvalued in 2026?

Based on GuruFocus' analysis, Century Therapeutics stock appears to be undervalued. The current stock price of $2.32 is trading 94.1% below its estimated GF Value™ of $38.91. GuruFocus considers Century Therapeutics to be Possible Value Trap.

Key valuation signals for IPSC:

  • Beta: 2.4506
  • GF Value™: $38.91 vs. price of $2.32 (94.1% below fair value)
  • GF Score™: 46/100 with 3 warning signs

No single metric tells the full story. See the IPSC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Century Therapeutics Business Description

Address 25 N 38th Street, 11th Floor, Philadelphia, PA, USA, 19104
Century Therapeutics Inc is a biotechnology company harnessing the power of allogeneic pluripotent stem cell therapies to develop potentially curative cell therapy products for autoimmune diseases, including type 1 diabetes, or T1D, and cancer. Its beta islet, T cell and NK cell programs are allogeneic, meaning it is derived from healthy donors for use in any patient, rather than being sourced from an individual for their own specific use, as is the case with autologous T cells. The cell types it can generate from iPSCs, including iPSC-derived beta islet cells, iPSC-derived CD4+ and CD8+ alphabeta T cells, or alphabeta iT cells, and iPSC- natural killer cells, or iNK cells.
46GF Score

Get the complete analysis for IPSC

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.32
Price
$38.91
GF Value